الرئيسية › سرطان الرئة › ماساتشوستس › Boston
التجارب السريرية لـ سرطان الرئة في Boston، MA
62 دراسات لـ سرطان الرئة تبحث عن مشاركين في مواقع داخل وحول Boston (ضمن نطاق 30 ميلًا تقريبًا). افتح الدراسة لمعرفة من يمكنه المشاركة وكيفية التواصل مع فريق الدراسة.
النص الرسمي للدراسة (بالإنجليزية)
Neladalkib (NVL-655) for TKI-naive Patients With Advanced ALK-Positive NSCLC
جارٍ التسجيلالمرحلة 3
- Dana-Farber Cancer Institute, Boston
Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])
جارٍ التسجيلالمرحلة 3
- Boston Medical Center, Boston
- Beth Israel Deaconess Medical Center, Boston
- Dana-Farber Cancer Institute, Boston
Chemotherapy Combined With Immunotherapy Versus Immunotherapy Alone for Older Adults With Stage IIIB-IV Lung Cancer, The ACHIEVE Trial
جارٍ التسجيلالمرحلة 3
- Tufts Medical Center, Boston
A Study of PHN-012 in Patients With Advanced Solid Tumors
جارٍ التسجيلالمرحلة 1
- PHN-012-001 Site, Boston
A Registry for People With Lung Cancer
جارٍ التسجيلدراسة رصدية
- Massachusetts General Hospital Cancer Center (Data Collection Only), Boston
- Brigham and Women's Hospital (Data Collection Only), Boston
Neoadjuvant and Adjuvant Treatment in Resectable Non-small Cell Lung Cancer
جارٍ التسجيلالمرحلة 2
- Research Site, Boston
A Study to Compare the Combination of Navlimetostat (BMS-986504) With Pembrolizumab and Chemotherapy Versus Placebo Plus Pembrolizumab and Chemotherapy in First-line Metastatic Non-small Cell Lung Cancer Participants With Homozygous MTAP Deletion
جارٍ التسجيلالمرحلة 2/3
- Dana-Farber Cancer Institute, Boston
Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid Tumors
جارٍ التسجيلالمرحلة 1/2
- Dana Farber Cancer Institute, Boston
Study of Izalontamab Brengitecan (BMS-986507) Versus Platinum-Pemetrexed for EGFR-mutated Non-small Cell Lung Cancer After Failure of EGFR TKI Therapy (IZABRIGHT-Lung01)
جارٍ التسجيلالمرحلة 2/3
- Dana-Farber Cancer Institute, Boston
A First-in-Human Trial of BLU-924 (SAR449336) in Advanced Solid Tumors Harboring KRAS Mutations
جارٍ التسجيلالمرحلة 1/2
- Massachusetts General Hospital - Main Campus, Boston
Study of RMC-5127 in Patients With Advanced KRAS G12V-Mutant Solid Tumors
جارٍ التسجيلالمرحلة 1
- Dana-Farber Cancer Institute, Boston
Phase 1/2 Trial of S241656 in Selected RAS/MAPK Mutation- Positive Malignancies
جارٍ التسجيلالمرحلة 1/2
- Dana-Farber Cancer Institute, Boston
The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
جارٍ التسجيلالمرحلة 1/2
- Massachusetts General Hospital, Boston
- Dana Farber Cancer Institute, Boston
Open Label Study to Evaluate BL-M07D1 in HER2 Expressing Malignant Solid Tumors
جارٍ التسجيلالمرحلة 1
- Dana Farber Cancer Institute, Boston
Stereotactic Brain-directed Radiation With or Without Aguix Gadolinium-Based Nanoparticles in Brain Metastases
جارٍ التسجيلالمرحلة 2
- Brigham and Women's Hospital, Boston
- Dana Farber Cancer Institute, Boston
Open-Label Study of BBO-10203 in Subjects With Advanced Solid Tumors
جارٍ التسجيلالمرحلة 1
- Massachusetts General Hospital, Boston
- Dana-Farber Cancer Insitute, Boston
A Study Evaluating the Efficacy and Safety of Divarasib and Pembrolizumab Versus Pembrolizumab and Pemetrexed and Carboplatin or Cisplatin in Participants With Previously Untreated, KRAS G12C-Mutated, Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer
جارٍ التسجيلالمرحلة 3
- Massachusetts General Hospital, Boston
A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer
جارٍ التسجيلالمرحلة 3
- Boston Medical Center, Boston
A Study of LY4050784 in Participants With Advanced or Metastatic Solid Tumors
جارٍ التسجيلالمرحلة 1
- Massachusetts General Hospital, Boston
- Dana-Farber Cancer Institute, Boston
AVENTINE-1: Study of AVZO-1418 as a Single Agent and in Combination Therapy in Patients With Locally Advanced or Metastatic Solid Tumors (AVZO-1418-1001)
جارٍ التسجيلالمرحلة 1/2
- Avenzo Therapeutics Recruiting Site, Boston
Investigating Hereditary Risk In Thoracic Cancers (INHERIT)
جارٍ التسجيلدراسة رصدية
- Brigham and Women's Hospital, Boston
- Dana-Farber Cancer Institute, Boston
Practical Geriatric Assessment in Older Adults With Non-Small Cell Lung Cancer Undergoing Stereotactic Body Radiation Therapy
جارٍ التسجيل
- Brigham and Women's Hospital, Boston
LEGACY: Lung Cancer Screening in Individuals With a Lung Cancer Family History-Protocol B
جارٍ التسجيلدراسة رصدية
- Massachusetts General Hospital, Boston
InAdvance: Surveillance, Prevention, and Interception in a Population at Risk for Cancer
جارٍ التسجيلدراسة رصديةمرحباً بالمتطوعين الأصحاء
- Dana Farber Cancer Institute, Boston
A Study of a Selective T Cell Receptor (TCR) Targeting, Bifunctional Antibody-fusion Molecule STAR0602 in Participants With Advanced Solid Tumors
جارٍ التسجيلالمرحلة 1/2
- Massachusetts General Hospital Cancer Center, Boston
Preliminary Efficacy of Different Exercise Training During Immunotherapy in Patients With Lung Cancer: The ENHANCE Trial
جارٍ التسجيل
- Dana-Farber Cancer Institute, Boston
Distance-Based Exercise to Preserve Function and Prevent Disability
جارٍ التسجيل
- Dana-Farber Cancer Institute, Boston
Precise Exercise Regimen for Cancer Care (PERCC): A Pilot Study
جارٍ التسجيل
- Dana-Farber Cancer Institute, Boston
Ivonescimab Alone And With Carboplatin/Pemetrexed For NSCLC
جارٍ التسجيلالمرحلة 2
- Massachusetts General Hospital, Boston
- Beth Israel Deaconess Medical Center, Boston
- Dana-Farber Cancer Institute, Boston
A Study of Peluntamig (PT217) in Patients With Neuroendocrine Carcinomas Expressing DLL3 (the SKYBRIDGE Study)
جارٍ التسجيلالمرحلة 1/2
- Massachusetts General Hospital, Boston
- Dana-Farber Cancer Institute, Boston
EQUAL: EGFR ctDNA QUantative Assessment for Lung Cancer Screening in Asian and Latinx Populations
جارٍ التسجيلمرحباً بالمتطوعين الأصحاء
- Beth Israel Deaconess Medical Center, Boston
- Dana-Farber Cancer Institute, Boston
- Massachusetts General Hospital, Boston
Mobile Application to Improve Health-Related Outcomes in Patients With Advanced Lung Cancer
جارٍ التسجيل
- Massachusetts General Hospital, Boston
Study of NXP900 With Osimertinib in Subjects With Advanced, EGFR-Mutated Non-Small Cell Lung Cancer
جارٍ التسجيلالمرحلة 1
- Massachusetts General Hospital, Boston
Study of RAS(ON) Inhibitors in Patients With Advanced RAS-mutated NSCLC
جارٍ التسجيلالمرحلة 1/2
- Dana Farber Cancer Institute, Boston
Clonal Hematopoiesis Chemotherapy and Radiation Effects Study
جارٍ التسجيلدراسة رصدية
- Dana-Farber Cancer Institute, Boston
A Phase 1 Dose-escalation Trial of KST-6051 in Participants With Advanced Solid Tumors With Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Mutation
جارٍ التسجيلالمرحلة 1
- Mass General Brigham Cancer Institute at Massachusetts General Hospital, Boston
Prediction Augmented Screening Initiative
جارٍ التسجيل
- VA Boston Healthcare System Jamaica Plain Campus, Jamaica Plain, MA, Boston
A Study to Learn About Study Medicine ALTA3263 in Adults With Advanced Solid Tumors With KRAS Mutations
جارٍ التسجيلالمرحلة 1
- Research Site, Boston
- Research Site, Boston
Study of RMC-9805 in Participants With KRAS G12D-Mutant Solid Tumors
جارٍ التسجيلالمرحلة 1
- Massachusetts General Hospital, Boston
- Dana-Farber Cancer Institute, Boston
A Study of Repotrectinib (TPX-0005) in Patients With Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 Rearrangements
جارٍ التسجيلالمرحلة 1/2
- Massachusetts General Hospital,, Boston
Study of RMC-6236 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RAS
جارٍ التسجيلالمرحلة 1/2
- Dana Farber Cancer Institute, Boston
Study to Evaluate the Safety, Tolerability & Efficacy of TNG462 in Combination in PDAC & NSCLC Patients
جارٍ التسجيلالمرحلة 1/2
- Massachusetts General Hospital, Boston
- Dana-Farber Cancer Institute, Boston
Deep Learning Using Chest X-Rays to Identify High Risk Patients for Lung Cancer Screening CT
جارٍ التسجيل
- Massachusetts General Hospital, Boston
A Phase 1/2 Study of VS-7375 in Patients With KRAS G12D-Mutated Solid Tumors
جارٍ التسجيلالمرحلة 1/2
- Massachusetts General Hospital, Boston
Safety and Tolerability of TNG456 Alone and in Combination With Abemaciclib in Patients With Solid Tumors With MTAP Loss
جارٍ التسجيلالمرحلة 1/2
- Dana Farber Cancer Institute, Boston
Avecure Flexible Microwave Ablation Probe For Lung Nodules
جارٍ التسجيل
- Beth Israel Deaconess Medical Center, Boston
A Digital Health Intervention to Improve Physical Function and Wellness of Lung Cancer Survivors
جارٍ التسجيل
- Massachusetts General Hospital, Boston
A Study Evaluating FMC-376 in Participants With KRAS G12C Mutated Solid Tumors
جارٍ التسجيلالمرحلة 1/2
- Dana-Farber Cancer Institute, Boston
Telephone-based Physical Activity Coaching or Self Monitored Physical Activity to Improve Physical Function in Older Adults Who Are Undergoing Surgery for Lung Cancer and Their Caregivers
جارٍ التسجيلمرحباً بالمتطوعين الأصحاء
- Massachusetts General Hospital (MGH) / Harvard, Boston
Maximizing Lymph Node Dissection on Fresh and Fixed Lung Cancer Resection Specimens
جارٍ التسجيلمرحباً بالمتطوعين الأصحاء
- Brigham and Womens Hospital, Boston
Evaluation of PET Probe [68Ga]CBP8 in the Detection of Radiation Induced Tissue Injury
جارٍ التسجيلالمرحلة 2
- Massachusetts General Hospital, Boston
Preliminary Evaluation of [68Ga]CBP8 in Healthy Individuals, Lung Cancer, and Idiopathic Pulmonary Fibrosis Patients
جارٍ التسجيلالمرحلة 1مرحباً بالمتطوعين الأصحاء
- Massachusetts General Hospital, Boston
Lung Cancer Screening in High-risk Black Individuals
جارٍ التسجيلمرحباً بالمتطوعين الأصحاء
- Massachusetts General Hospital Cancer Center, Boston
Veterans Affairs Lung Cancer Surgery Or Stereotactic Radiotherapy
جارٍ التسجيل
- VA Boston Healthcare System Jamaica Plain Campus, Jamaica Plain, MA, Boston
Image Guided VATS vs. VATS Resection
جارٍ التسجيل
- Brigham and Women's Hospital, Boston
Stereotactic Magnetic Resonance Guided Radiation Therapy
جارٍ التسجيل
- Brigham & Women's Hospital, Boston
- Dana Farber Cancer Institute, Boston
Health Opportunities and Promoters of Equitable Screening for Lung Cancer
جارٍ التسجيلدراسة رصدية
- Massachusetts General Hospital, Boston
A Study to Evaluate TROP2 ADC LCB84 Single Agent and in Combination With an Anti-PD-1 Ab in Advanced Solid Tumors
جارٍ التسجيلالمرحلة 1/2
- Dana Farber Cancer Institute, Boston
Comprehensive Outcomes for After Cancer Health
جارٍ التسجيلمرحباً بالمتطوعين الأصحاء
- Dana Farber Cancer Institute, Boston
DNA Analysis of Blood and Tissue from Patients with Lung Cancer
جارٍ التسجيلدراسة رصديةمرحباً بالمتطوعين الأصحاء
- Massachusetts General Hospital, Boston
- Harvard School of Public Health, Boston
Molecular and Genetic Analysis of Lung Cancer
جارٍ التسجيلدراسة رصديةمرحباً بالمتطوعين الأصحاء
- Massachusetts General Hospital, Boston
Clinical Utility of Management of Patients With Pulmonary Nodules Using the Percepta Nasal Swab Classifier
جارٍ التسجيلدراسة رصدية
- Boston University Medical Center, Boston
تجارب سرطان الرئة في مدن أخرى
- Houston, TX78 دراسات
- New York City, NY60 دراسات
- Los Angeles, CA45 دراسات
- Washington, DC41 دراسات
- Chicago, IL41 دراسات
- Arlington, VA40 دراسات
- Nashville, TN40 دراسات
- Baltimore, MD40 دراسات
- St. Louis, MO39 دراسات
- Columbus, OH36 دراسات
- Philadelphia, PA36 دراسات
- Seattle, WA33 دراسات
دراسات أخرى في Boston
- سرطان الثدي110 دراسات
- سرطان الرئة غير صغير الخلايا89 دراسات
- السرطان (جميع الأنواع)86 دراسات
- سرطان القولون والمستقيم63 دراسات
- السرطان النقيلي63 دراسات
- سرطان المبيض61 دراسات
- سرطان البروستاتا60 دراسات
- الاكتئاب51 دراسات
- سرطان بطانة الرحم50 دراسات
- ابيضاض الدم النقوي الحاد45 دراسات
- سرطان البنكرياس44 دراسات
- قصور القلب43 دراسات
من ClinicalTrials.gov، البيانات مستخرجة في 01/10/2026. كل دراسة تحدد معايير أهليتها الخاصة؛ فريق الدراسة هو من يحدد من يمكنه المشاركة.